Construction and Validation of a Potent Epigenetic Modification-Related Prognostic Signature for Osteosarcoma Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background. Increasing evidence has shown that tumorigenesis correlates with aberrant epigenetic factors, such as DNA methylation, histone modification, RNA m6A modification, RNA binding proteins, and transcription factors. However, it is unclear that how epigenetic genes linked with alteration contribute to osteosarcoma’s incidence and clinical prognosis. We developed an epigenetic modification-related prognostic model that may improve the diagnosis and prognosis of osteosarcoma. Methods. We investigated the epigenetic modification-associated genes and their clinical significance in osteosarcoma in this research. Our gene transcriptome data were obtained from the TARGET database and the GEO database. Bioinformatics techniques were used to investigate their functionalities. The diagnostic and prognostic models were constructed using univariate and multivariate Cox regression. In addition, we developed a nomogram indicating the practicability of the prognostic model described above. Results. A risk score model constructed based on four epigenetic modification-related genes (MYC, TERT, EIF4E3, and RBM34) can effectively predict the prognosis of patients with osteosarcoma. Based on the risk score and clinical features, we constructed a nomogram. Conclusion. Epigenetic modification-related genes have been identified as important prognostic markers that may assist in osteosarcoma therapy therapeutic decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 6×
“We used Gene Set Enrichment Analysis (GSEA) [20] in the TARGET dataset to examine differences between high-and low-risk patients identified by prognostic models consisting of EMGs.”
MethodInfluentialSzklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1074 · Cited by 8,056 · cited 1×
“We used Cytoscape software to analyze a PPI network with 531 nodes and 2941 edges constructed from the STRING database [22] (Figure 4(a)) to investigate the function of differentially expressed EMGs in osteosarcoma.”
MethodThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · cited 1×
“Many elements of epigenetic alteration controlling gene expression that interfere with tumor development have been discovered by scientists in recent decades [23, 24].”
BackgroundReinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887 · cited 1×
“gov/cellminer) [21], which includes 60 different cancer cell lines from nine different malignancies.”
BackgroundCistrome: an integrative platform for transcriptional regulation studies
Liu, T., Ortiz, J. A., Taing, L., Meyer, C. A., Lee, B., Zhang, Y., Shin, H., Wong, S. S., Ma, J., Lei, Y., et al. (2011) · Genome Biology · doi:10.1186/gb-2011-12-8-r83 · Cited by 716
Update on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336 · cited 1×
“Introduction &e most frequent primary malignant bone tumor is osteosarcoma, which is primarily caused by primitive malignant bone mesenchymal cells [1, 2].”
Background
Cited by
Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review
Twenhafel, L., Moreno, D., Punt, T., Kinney, M., & Ryznar, R. J. (2023) · Cells · doi:10.3390/cells12121595 · Cited by 38
“[73,74] TARGET database Prognostic Model EMGs and lncRNA levels used to assess patient prognosis and the 5-year survival rate”
BackgroundMethodYang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31
Systemic strategies for osteosarcoma: advances and future directions
Morya, V. K., Magar, A. G., Park, S., & Noh, K.-C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02208-9 · Cited by 32
Recent advances of m6A methylation in skeletal system disease
Liang, J., Yi, Q., Liu, Y., Li, J., Yang, Z., Sun, W., & Sun, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04944-y · Cited by 25
“Increasing evidences have reported that m6A regulators can act as prognostic biomarkers of OS [202].”
BackgroundZheng, D., Wei, Z., & Guo, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849789 · Cited by 15
Metadata
- Authors
- Liu, S., Wu, B., Li, X., Zhao, L., Wu, W., & Ai, S.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Ai, Songtao
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2021-11-22
- Volume
- 2021
- Pages
- 1-14
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- PMC
- PMC8629625
- OpenAlex
- W3215576535
- Cited by
- 15
- References
- 35
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- osteosarcoma, epigenetic modifications, prognostic signature, risk scoring, nomogram, c-Myc, telomerase reverse transcriptase, EIF4E3, DNA methylation, histone modifications, m6A RNA methylation, RNA-binding proteins, transcription factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Construction and Validation of a Potent Epigenetic Modification-Related Prognostic Signature for Osteosarcoma Patients. https://app.cochat.ai/papers/10.1155/2021/2719172
- The paper
- Liu, S., Wu, B., Li, X., Zhao, L., Wu, W., & Ai, S. (2021). Construction and Validation of a Potent Epigenetic Modification-Related Prognostic Signature for Osteosarcoma Patients. Journal of Oncology. https://doi.org/10.1155/2021/2719172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.